Neurocrine Biosciences Inc (NBIX)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA and an Investment Account

Sell

$143.99

Buy

$160.99

arrow-down$-1.95 (-1.26%)

Prices updated at 12 Dec 2025, 09:21 EST

Prices minimum 15 mins delay

Prices in USD

Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Chairman

Dr. William H. Rastetter,PhD

CEO

Dr. Kyle W. Gano, PhD

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

1,800

Head office

6027 Edgewood Bend Court

San Diego

United States

92130

+1 858 617-7600

ir@neurocrine.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Sanjay Keswani, M.B.B.S. Chief Medical Officer	-
Mr. Gary A. Lyons Independent Director	0.07m
Dr. Kevin C. Gorman,PhD Director	0.78m
Mr. Richard F. Pops Independent Director	0.09m
Ms. Shalini Sharp Independent Director	0.10m
Dr. William H. Rastetter,PhD Chairman of the Board	0.10m
Ms. Christine A. Poon Independent Director	0.08m
Mr. George J. Morrow Independent Director	0.08m
Dr. Stephen A. Sherwin, M.D. Independent Director	0.09m
Mr. Eric S. Benevich Chief Commercial Officer	0.64m
Mr. Darin M. Lippoldt Chief Legal Officer and Corporate Secretary	-
Ms. Leslie V. Norwalk, Esq. Independent Director	0.08m
Dr. Kyle W. Gano, PhD Director, President and Chief Executive Officer	0.70m
Mr. Matthew C. Abernethy Chief Financial Officer and Principal Accounting Officer	0.68m
Ms. Julie S. Cooke Chief Human Resources Officer	-
Ms. Johanna Mercier Independent Director	0.07m
Mr. David W. Boyer Chief Corporate Affairs Officer	-
Dr. Jude Onyia, PhD Chief Scientific Officer	0.68m
Dr. Ingrid Delaet, PhD Chief Regulatory Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	12,706,230
Vanguard Group Inc	9,807,066
JPMorgan Chase & Co	9,460,304
BlackRock Fund Advisors	6,829,727
Dodge & Cox	5,556,618

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
31 Dec 2024	-
31 Dec 2024	-
17 Dec 2024	-
17 Dec 2024	-
17 Dec 2024	-
17 Dec 2024	-
17 Dec 2024	-
29 Nov 2024	-
29 Nov 2024	-
29 Nov 2024	-
08 Nov 2024	-
08 Nov 2024	-
08 Nov 2024	-
08 Nov 2024	-
08 Nov 2024	-
08 Nov 2024	-
08 Nov 2024	-
08 Nov 2024	-
04 Nov 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.